{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:37:46Z","timestamp":1780439866997,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,18]]},"DOI":"10.1093\/ibd\/izx001","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T20:21:30Z","timestamp":1516306890000},"page":"380-386","source":"Crossref","is-referenced-by-count":83,"title":["Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy"],"prefix":"10.1093","volume":"24","author":[{"suffix":"Jr","given":"Perry K","family":"Pratt","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunes","family":"David","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst C","family":"Weber","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric F","family":"Little","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Allergy, Sleep & Critical Care Medicine, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Kourkoumpetis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Patts","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"key\n\t\t\t\t20180413115359_CIT0001","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2036.2010.04570.x","article-title":"Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease","volume":"33","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180413115359_CIT0002","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/jgh.13001","article-title":"Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients","volume":"30","author":"Andrade","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180413115359_CIT0003","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.vaccine.2009.10.068","article-title":"Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis","volume":"28","author":"Poorolajal","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180413115359_CIT0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","article-title":"Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action","volume":"29","author":"Carroll","year":"2010","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20180413115359_CIT0006","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180413115359_CIT0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00054725-200409000-00035","article-title":"Infliximab therapy in a patient with Crohn\u2019s disease and chronic hepatitis B virus infection","volume":"10","author":"del Valle Garcia-Sanchez","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0008","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MIB.0b013e31827febe9","article-title":"Kinetics of anti\u2013hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease","volume":"19","author":"Gisbert","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"key\n\t\t\t\t20180413115359_CIT0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guidelines: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0010","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part I & II","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR"},{"key":"key\n\t\t\t\t20180413115359_CIT0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0149-2918(01)80044-8","article-title":"Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines","volume":"23","author":"Coates","year":"2001","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180413115359_CIT0012","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","article-title":"Guidelines for immunizations in patients with inflammatory bowel disease","volume":"10","author":"Sands","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0013","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.vaccine.2010.01.059","article-title":"Improved anamnestic response among adolescents boosted with a higher dose of the hepatitis B vaccine","volume":"28","author":"Chaves","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180413115359_CIT0014","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ajg.2011.295","article-title":"Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab","volume":"107","author":"Moses","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0015","first-page":"589","article-title":"Hepatitis B vaccines: WHO position paper \u2013 recommendations","volume":"28","author":"WHO Publication","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180413115359_CIT0016","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","article-title":"Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)","volume":"8","author":"Loras","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180413115359_CIT0017","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(99)07239-6","article-title":"Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180413115359_CIT0018","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Marin","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"9","key":"key\n\t\t\t\t20180413115359_CIT0019","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.cgh.2017.02.005","article-title":"Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis","volume":"15","author":"Qiu","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180413115359_CIT0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10620-005-1295-8","article-title":"Infliximab therapy for Crohn\u2019s disease in a patient with chronic hepatitis B","volume":"50","author":"Ueno","year":"2015","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180413115359_CIT0021","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn\u2019s disease: need for HBV-screening","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0022","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ibd.20216","article-title":"Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn\u2019s disease","volume":"13","author":"Colbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0023","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/ibd.20202","article-title":"Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn\u2019s disease patient","volume":"13","author":"Esteve","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0024","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180413115359_CIT0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0026","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00535-008-2165-x","article-title":"Reactivation of hepatitis B in a patient with Crohn\u2019s disease treated using infliximab","volume":"43","author":"Ojiro","year":"2008","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0027","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ddr.21193","article-title":"Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients","volume":"75","author":"Ballanti","year":"2014","journal-title":"Drug Dev Res"},{"key":"key\n\t\t\t\t20180413115359_CIT0028","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-009-1149-4","article-title":"Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients","volume":"7","author":"Li","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"2","key":"key\n\t\t\t\t20180413115359_CIT0029","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180413115359_CIT0031","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MEG.0b013e3283329d13","article-title":"Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B","volume":"4","author":"Verhelst","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180413115359_CIT0032","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations","volume":"21","author":"Mori","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180413115359_CIT0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalance and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain; a nationwide, multicenter study","volume":"104","author":"Loras","year":"2009","journal-title":"Am J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/2\/380\/24616068\/izx001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T15:54:08Z","timestamp":1523634848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/2\/380\/4816928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,18]]},"published-print":{"date-parts":[[2018,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx001","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2018,1,18]]}}}